Targeting Inflammation to Address Rheumatoid Diseases

Monday October 28, 2019

Abcentra is working on clinical and preclinical programs focused on addressing unmet needs in inflammatory diseases. Inflammation is a primary driver behind many fatal and life-threatening conditions, including many types of rheumatoid diseases.

In the remote past, certain types of rheumatoid diseases have fallen under the broad heading of ‘rheumatism.’ Now, there are more than 200 distinct types of rheumatoid diseases. Among the many rheumatic diseases, rheumatoid arthritis and psoriatic arthritis are the two most pertinent types caused by inflammation, and where oxidized low-density lipoprotein (oxLDL) may be implicated.

Rheumatoid Arthritis (RA) is a chronic disease that affects about 1.5 million people in the United States. It is mainly characterized by inflammation of the lining, or synovium, of the joints. However, RA affects the other organ systems as well, including the cardiovascular or respiratory systems, and thus is called a systemic disease; meaning “entire body.”

Psoriatic arthritis (PsA) is a chronic disease characterized by inflammation of the skin (psoriasis) and joints (arthritis). PsA affects about 30 percent of people with psoriasis. There is no cure for PsA, only a range of treatments to stop the disease progression, lessen pain, and preserve range of motion. Both psoriasis and psoriatic arthritis involve inflammation and are often related; however, not everyone who has psoriasis will get psoriatic arthritis. Similar to RA, both psoriasis and psoriatic arthritis occur because of inflammation, with the immune system to attacking one’s own body.

Abcentra is working on treatments specifically targeting oxLDL, an inflammatory mediator that is implicated in certain types of rheumatoid diseases including psoriasis and rheumatoid arthritis. Abcentra’s lead candidate, orticumab, is the first and only fully-human monoclonal antibody of its kind developed to treat plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid disease. By targeting oxLDL and the underlying cause of inflammation, Abcentra aims to bring new, safer and more effective treatment options to patients with rheumatoid diseases.

For more information about our lead candidate, read more about our science, or view our pipeline to learn more about the other treatment options currently in development.